European evidence‐based (S3) guideline for the treatment of acne – update 2016 – short version
Alexander Nast(Humboldt-Universität zu Berlin), Harald Gollnick(University Hospital Magdeburg), A.Y. Finlay(Cardiff University), Corinna Dressler(Charité - Universitätsmedizin Berlin), J.L. López‐Estebaranz(Hospital Universitario Fundación Alcorcón), Jacques Lambert(University of Antwerp), Thierry Simonart(IS practice), Alison Layton(University of York), Stefanie Rosumeck(Charité - Universitätsmedizin Berlin), Falk Ochsendorf(University Hospital Frankfurt), Merete Hædersdal(University of Copenhagen), Ricardo Niklas Werner(Charité - Universitätsmedizin Berlin), Zrinka Bukvić Mokoš(University of Zagreb), Hans B. Lomholt(Aarhus University), Cristina Oprica(Karolinska Institutet), Vincenzo Bettoli(University of Ferrara), Klaus Degitz, Brigitte Dréno(Nantes Université)
Cited by 378
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
|Clinical and Experimental Dermatology|1994|5.5k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k